SCHEMBL2635722

SCHEMBL2635722

COC(=O)c1cc(OCC(=O)Cl)c2c(Cl)cc(Cl)cc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
HTT P42858 2/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
XBP1 P17861 1/20 0.37
KMT2A Q03164 1/20 0.37
PTPN11 Q06124 1/20 0.37
CYP3A4 P08684 1/20 0.37
S1PR4 O95977 1/20 0.36
ACLY P53396 1/20 0.36
RAB9A P51151 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
YTHDC1 Q96MU7 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635943 0.90 TDP1 (0.49) MAPTSMN1; SMN2ALDH1A1TDP1TSHR
SCHEMBL2635847 0.85 GAA (0.42) LMNAMAPTALDH1A1TDP1TSHR
SCHEMBL2635997 0.84 ACLY (0.44) LMNAMAPTSMN1; SMN2ALDH1A1TDP1
SCHEMBL2635555 0.83 MAPT (0.52) LMNAMAPTSMN1; SMN2ALDH1A1TDP1
SCHEMBL2635524 0.83 NPC1 (0.49) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL2636019 0.81 MAPT (0.50) LMNAMAPTSMN1; SMN2ALDH1A1TDP1
SCHEMBL2635914 0.81 ALDH1A1 (0.42) MAPTSMN1; SMN2ALDH1A1HTTTSHR
SCHEMBL2636251 0.81 RAB9A (0.56) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL2635387 0.80 ALDH1A1 (0.54) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL2634516 0.79 ALDH1A1 (0.42) LMNAMAPTSMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 LMNA 1894/4885MAPT 1202/4885SMN1; SMN2 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.